Aspire Biopharma为快速反应的亚语言迷幻药申请专利,治疗运动疾病。 Aspire Biopharma files patent for fast-acting sublingual meclizine to treat motion sickness.

Aspire Biopharma公司已申请临时专利,以获得一种速效的亚语粉末形式的meclizine,这是Dramamine的通用成分,目的是为减病运动提供一种反应更快的替代品。 Aspire Biopharma has filed a provisional patent application for a fast-acting sublingual powder form of meclizine, the generic ingredient in Dramamine, aiming to provide a quicker-acting alternative for motion sickness relief. 新配方旨在溶解在舌头之下,可能比传统的口服药片更快地吸收。 The new formulation is designed to dissolve under the tongue, potentially offering faster absorption than traditional oral tablets. 该公司未披露开发时间表或临床试验计划。 The company did not disclose development timelines or clinical trial plans.